C4 Therapeutics (CCCC) Retained Earnings (2019 - 2026)
C4 Therapeutics (CCCC) posted quarterly Retained Earnings of -$322000.0 for Q1 2026, up 99.95% year-over-year from -$161039.3 in Q1 2025, and up 99.96% quarter-over-quarter from -$738.7 million in Q4 2025.
C4 Therapeutics (CCCC) Retained Earnings (2019 - 2026) Analysis & Trends
C4 Therapeutics' Retained Earnings history runs 8 years deep, the most recent figure standing at -$322000.0 for Q1 2026.
- In Q1 2026, Retained Earnings rose 99.95% year-over-year to -$322000.0; the TTM figure through Mar 2026 stood at -$322000.0 (up 99.95% YoY), while the FY2025 annual figure was -$738.7 million, down 16.57% from the prior year.
- Retained Earnings for Q1 2026 stood at -$322000.0, up from -$738.7 million in the prior quarter.
- The five-year high for Retained Earnings was $87000.0 in Q3 2025, with the low at -$738.7 million in Q4 2025.
- The 5-year median for Retained Earnings is -$4.6 million (2022), against an average of -$229.9 million.
- The sharpest annual moves came in 2024 and 2025: Retained Earnings sank 498875.59% in 2024, then jumped 100.01% in 2025.
- C4 Therapeutics' Retained Earnings stood at -$4.1 million in 2022, then jumped by 96.93% to -$127000.0 in 2023, then tumbled by 498875.59% to -$633.7 million in 2024, then decreased by 16.57% to -$738.7 million in 2025, then surged by 99.96% to -$322000.0 in 2026.
- Business Quant data shows CCCC's Retained Earnings at -$322000.0 in Q1 2026, -$738.7 million in Q4 2025, and $87000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | C4 Therapeutics | 521.12 Mn | 267.46 Mn | - | -787.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -787.50 Mn |
| Mar 31, 2026 | -322,000.00 |
| Dec 31, 2025 | -738.69 Mn |
| Sep 30, 2025 | 87,000.00 |
| Jun 30, 2025 | -30,000.00 |
| Mar 31, 2025 | -660.02 Mn |
| Dec 31, 2024 | -633.70 Mn |
| Sep 30, 2024 | -599.13 Mn |
| Jun 30, 2024 | -440,000.00 |
| Mar 31, 2024 | -380,000.00 |
| Dec 31, 2023 | -127,000.00 |
| Sep 30, 2023 | -493.60 Mn |
| Jun 30, 2023 | -466.60 Mn |
| Mar 31, 2023 | -2.47 Mn |
| Dec 31, 2022 | -4.14 Mn |
| Sep 30, 2022 | -5.41 Mn |
| Jun 30, 2022 | -4.58 Mn |
| Mar 31, 2022 | -299.34 Mn |
| Dec 31, 2021 | -775,000.00 |
| Sep 30, 2021 | -252.06 Mn |